PerkinElmer, Inc., a global leader focused on the health and safety of people and the environment, today launched the latest expansion of the EnSpire™ Multilabel Plate Reader platform ─ EnSpire, with ultra sensitive luminescence detection. This new detection capability provides scientists, including those working with primary or stem cells in cancer and neuropharmacology research, with enhanced capabilities to improve assay performance and sensitivity.
The EnSpire platform features a configurable plate reader that delivers high performance detection and easy to use software. The affordable platform is adaptable for use in laboratories of many sizes with diverse research applications. This module expansion adds ultra sensitive luminescence detection, temperature control and fluorescence intensity (FI) bottom reading capabilities for both 96- and 384-well formats. Scientists working with limited numbers of cells can now generate enhanced assay signals, leading to improved assay performance and precision.
Nance Hall, vice president and general manager, Automation and Detection Solutions, Bio-discovery, PerkinElmer, said, “In areas where every cell is precious, and research resources are limited, EnSpire’s luminescence sensitivity overcomes the challenges presented by applications where cell availability and low transfection rates may limit dynamic range and assay window optimization. The EnSpire platform, now with luminescence detection, enhances outcomes for those researchers running luminescence studies, particularly cell proliferation, cytotoxicity, and reporter gene assays.”
With the addition of ultra sensitive luminescence, the configurable EnSpire platform now offers the following key detection technology choices to address customer needs:
- Fluorescence Intensity (FI)
- Absorbance (Abs)
- Ultra-sensitive luminescence (new)
- Optional temperature control and bottom-reading FI (new)